Assembly Biosciences (ASMB) Free Cash Flow (2010 - 2026)

Assembly Biosciences' Free Cash Flow history runs 17 years deep, the most recent figure standing at -$22.1 million for Q1 2026.

• On a quarterly basis, Free Cash Flow rose 5.64% year-over-year to -$22.1 million in Q1 2026; TTM through Mar 2026 was -$39.8 million, a 29.13% increase from a year earlier, with the FY2025 full-year figure at -$41.2 million, up 19.52% from the prior year.
• Free Cash Flow eased to -$22.1 million in Q1 2026 per ASMB's latest filing, from $14.2 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $74.4 million in Q4 2023 and bottomed at -$28.0 million in Q1 2022.
• The 5-year median for Free Cash Flow is -$17.1 million (2024), against an average of -$10.3 million.
• Across the five-year window, Free Cash Flow tumbled 100.55% in 2024 and surged 3592.14% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$18.3 million in 2022, then soared by 505.76% to $74.4 million in 2023, then tumbled by 100.55% to -$407000.0 in 2024, then jumped by 3592.14% to $14.2 million in 2025, then slumped by 255.6% to -$22.1 million in 2026.
• Per Business Quant, the three latest ASMB Free Cash Flow figures stand at -$22.1 million (Q1 2026), $14.2 million (Q4 2025), and -$15.2 million (Q3 2025).